Monday, July 26, 2010

Immune Design Raises $32M

Seattle-based Immune Design Corp., a biotech firm focused on treatments for infectious disease and cancer, said today that it has raised $32M in a Series B funding round. The round was led by ProQuest Investments, and also included current investors The Column Group, Verant Ventures, and Alta Partners. Immune design is applying vaccine and immunotherapy techniques to treating infectious diseases and cancer. The firm said that ProQuest's Alain Schreiber joins the firm's board as part of the funding. Immune Design Corp. has now raised over $50M in funding, the firm said. More information »